Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282659 · ClinicalTrials.gov registry record · Phase 4
The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control
A Phase 4 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 240
- Enrollment target
NCT00282659 is a Phase 4 study that has completed, run by Hartford Hospital. The registered enrollment target is 240 participants.
The verdict
NCT00282659, a Phase 4 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if magnesium can improve blood pressure, cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators (ICDs).
Interventions
- DRUG magnesium L-lactate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282659
The ClinicalTrials.gov registry entry for NCT00282659 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which magnesium L-lactate is the first listed.
NCT00282659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282659 about?
NCT00282659 is a clinical study titled "The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control". The purpose of this study is to determine if magnesium can improve blood pressure, cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators (ICDs).
What is the current status of trial NCT00282659?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 240 participants. The study started on 2006-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00282659?
The interventions under investigation include: magnesium L-lactate (DRUG).
Who is sponsoring clinical trial NCT00282659?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.